Clinical Trial Search

Primary: Percentage Time Spent Above Glucose Thresholds (>110;>144;>180) 24-48 Hours Post Betamethasone Treatment — 73; 79; 40; 58 percentage time

Primary: Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge) — 0 Subjects

Primary: Maximum Observed Plasma Concentration (Cmax) of PF-00489791 — 1140; 1238; 1198; 1186 nanograms per milliliter (ng/mL)

Primary: Disease Control Rate — 13 % of participants with disease control

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 0 percentage of participants — p=< 0.001

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 100; 90; 100; 100 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 84.6; 96.4; 100.0; 100.0 percentage of participants

Primary: Depression Anxiety and Stress Scale (DASS) — 6.14; 5.23; 7.21; 5.62 units on a scale

Primary: Peak Systolic Pressure — 115.4; 121.3; 123.4; 122.1 mm Hg

Primary: Percentage of Participants With Achieved SVR12 (HCV RNA <LLOQ 12 Weeks After Completion of Treatment) — 97; 100 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.3; 100.0; 90.9; 100.0 percentage of participants

Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 12 Weeks of Treatment — 0.45; -0.03; -0.19 Percentage of HbA1c — p=0.3295

Primary: Distance Binocular LogMAR Visual Acuity — -1.072; -0.904; 0.9017; 0.557 -10*LogMAR

Primary: Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD) at 12 Months — 0.39; -0.21; -2.2 percent change

Primary: Post-operative Pain Measured by Visual Analogue Scale — 2.15; 2.02; 2.84; 2.72 units on a scale — p=.028